Pharmicell Co., Ltd. (KRX:005690)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,980
-140 (-1.07%)
Last updated: Jun 10, 2026, 2:13 PM KST
Market Cap787.08B +14.9%
Revenue (ttm)23.94B -3.6%
Net Income-26.78B
EPS-613.75
Shares Out 59.99M
PE Ration/a
Forward PE13.60
Dividend50.00 (0.38%)
Ex-Dividend DateDec 29, 2025
Volume420,383
Open13,030
Previous Close13,120
Day's Range12,810 - 13,870
52-Week Range10,360 - 21,150
Beta0.57
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impot... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1968
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 005690
Full Company Profile

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.

Financial Statements